Moderna Inc
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we treat and prevent diseases. Since its founding, Moderna's mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more. With a global team and a unique culture, driven by the company's values and mindsets, Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines.
Current Price
$48.12
+5.25%Profile
Valuation (TTM)
Market Cap$19.00B
P/E-5.95
EV$15.50B
P/B2.20
Shares Out394.94M
P/Sales8.54
Revenue$2.23B
EV/EBITDA—
Moderna Inc (MRNA) Stock Analysis
GoodMoat Analysis
Moderna is a biotechnology company with a potentially strong moat in mRNA technology, but it currently fails the initial quality gate for value investors. Its financials show deep losses and negative growth, making it an unfavourable candidate for traditional value analysis at this stage.
Read full analysis
Moderna Inc. is a biotechnology company that develops therapeutics and vaccines based on messenger RNA (mRNA) technology. Applying the GoodMoat framework, the company shows potential for a durable competitive advantage. It likely scores well in Moat Identification, particularly in Technology Leadership as a pioneer in approved mRNA products, Proprietary Data from its platform, and Strategic Partnerships. It may also score in Regulatory Barriers and Founder-Led Execution. A moat score of 5+ is plausible, allowing us to proceed to the Quality Gate. However, the company fails the Quality Gate decisively. The provided data shows multiple weak quality indicators: a negative P/E of -7.4, a Profit Margin of -145.2%, an Operating Margin of -158.1%, and a deeply negative ROE of -32.6%. Revenue growth is sharply negative at -29.8% YoY, and the Free Cash Flow Yield is -9.9%. These metrics indicate the company is not currently generating high returns or strong cash flows, which are prerequisites for a high-quality business under the framework. According to Section 6, a business with a Moat Score ≥5 but predominantly weak quality ratings does not pass the initial gate for further valuation analysis. The current financial profile is unfavourable for a value investor seeking durable profitability and financial strength, though its technology platform may warrant monitoring for a future turnaround in fundamentals. Analysis based on data as of 2024-05-15.
Market Cap$19.00B
Current Price$48.12
P/E Ratio-5.95
Forward P/E—
PEG Ratio-0.17
EPS$-7.26
Book Value$21.90
P/B Ratio2.20
MRNA Financial Charts
FCF vs CAPEX
FCFCAPEX
Cash vs Debt
Net Cash: 1.3B
Revenue
60M
FY19
803M
FY20
18.5B
FY21
19.3B
FY22
6.8B
FY23
3.2B
FY24
1.9B
FY25
Net Income
—
FY19
—
FY20
12.2B
FY21
8.4B
FY22
—
FY23
—
FY24
—
FY25
MRNA 52-Week Range
$22.36
$57.80
50-Day MA: $50.93200-Day MA: $36.85
Did you know?
MRNA's revenue grew at a 78.5% CAGR over the last 6 years.
Moderna Inc (MRNA) Financial Summary
Moderna Inc (MRNA) is a Healthcare company in the Biotechnology industry, listed on NASDAQ. The stock currently trades at $48.12 with a market capitalization of $19.00B.
Key valuation metrics include a P/E ratio of -5.95, price-to-book ratio of 2.20, and EPS of $-7.26. The company reports a profit margin of -143.6% and return on equity of -36.9%.
MRNA Key Financial Metrics
| Metric | Value |
|---|---|
| Market Cap | $19.00B |
| P/E Ratio | -5.95 |
| EPS | $-7.26 |
| P/B Ratio | 2.20 |
| P/S Ratio | 8.54 |
| Profit Margin | -143.6% |
| Return on Equity | -36.9% |
| Debt/Equity | 0.15 |
MRNA Revenue & Earnings History
| Year | Revenue | Net Income |
|---|---|---|
| FY19 | $60.00M | $-514.00M |
| FY20 | $803.00M | $-747.00M |
| FY21 | $18.47B | $12.20B |
| FY22 | $19.26B | $8.36B |
| FY23 | $6.85B | $-4.71B |
| FY24 | $3.24B | $-3.56B |
| FY25 | $1.94B | $-2.82B |
MRNA Quality Indicators
Moderna Inc maintains a profit margin of -143.6% and an operating margin of -158.1%. Return on equity stands at -36.9%. The current ratio is 3.29. Debt-to-equity ratio is 0.15.
About Moderna Inc
Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we treat and prevent diseases. Since its founding, Moderna's mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more. With a global team and a unique culture, driven by the company's values and mindsets, Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines.
MRNA Free Cash Flow
Moderna Inc generated $-2.08B in trailing twelve-month free cash flow, representing an FCF yield of -10.92%. This low FCF yield may reflect heavy reinvestment or growth spending.
MRNA Shares Outstanding
Moderna Inc has 0.39 billion shares outstanding at a share price of $48.12, giving it a market capitalization of $19.00B.
MRNA Recent Insider Trades
Recent insider transactions at Moderna Inc include:
| Insider | Type | Shares | Value |
|---|---|---|---|
| Hoge Stephen (President) | SELL | 53,336 | $2.58M |
| Hussain Abbas | SELL | 5,682 | $264951.66 |
| Klinger Shannon Thyme (Chief Legal Officer) | SELL | 13,885 | $726046.65 |